Fedratinib in 2025 and beyond: indications and future applications
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024015365
Abstract: Abstract Dysregulated JAK/STAT signaling underlies the pathogenesis of myelofibrosis, a myeloproliferative neoplasm characterized by cytopenias, splenomegaly, and constitutional symptoms. JAK inhibitors, such as fedratinib, are the primary therapeutic option for patients with high-risk or symptomatic… read more here.
Keywords: indications future; 2025 beyond; beyond indications; jak inhibitors ... See more keywords